ArticleFrontiers in oncology2026
Acute lymphoblastic leukemia presenting as myocardial infiltration mimicking hypertrophic cardiomyopathy: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lymphoblastic leukemia (ALL) with myocardial infiltration is a rare extramedullary manifestation, typically encountered in advanced or relapsed disease. Presentation as an isolated, reversible hypertrophic cardiomyopathy (HCM)-like phenotype without typical hematological symptoms is exceptional and poses a major diagnostic challenge. Case presentation: A 25-year-old man presented with fever, weight loss (20 kg over 3 months), progressive dyspnea, and bilateral lower extremity edema. Echocardiography and CMR imaging revealed severe asymmetrical left ventricular hypertrophy (maximum septal thickness 27 mm) with reduced left ventricular ejection fraction (as low as 27%), initially suggesting non-obstructive HCM. However, the presence of persistent fever, a marked inflammatory response (C-reactive protein 129 mg/L; reference: <10 mg/L), and elevated D-dimer and the lack of a family history or cardiovascular risk factors raised suspicion. Whole-body [ Conclusion: This case illustrates that T-ALL can first manifest as a rapidly progressive, HCM-mimicking cardiomyopathy that is fully reversible with effective chemotherapy. Clinicians should suspect hematologic malignancy in a young patient with unexplained cardiac hypertrophy associated with constitutional symptoms, elevated inflammatory markers, and poor response to standard therapy for heart failure. Early bone marrow examination and, if necessary, endomyocardial biopsy can confirm the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.